{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:30:50Z","timestamp":1790281850425,"version":"4.1.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK114857"],"award-info":[{"award-number":["P30DK114857"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:p>Diabetes and its associated complications pose an immediate threat to humankind. Diabetic kidney disease is one of the most devastating complications, increasing the risk of death more than ten-fold over the general population. Until very recently, the only drugs proven and recommended to slow the progression of diabetic kidney disease were angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers, which act by inhibiting the renin-angiotensin system. Despite their efficacy as kidney and cardiovascular protective therapies and as antihypertensive agents, renin-angiotensin system inhibitors have been grossly underutilized. Moreover, even when renin-angiotensin system inhibitors are used, patients still have a high residual risk of diabetic kidney disease progression. Finally, the kidney-protective effect of renin-angiotensin system inhibitors has been categorically demonstrated only in patients with macroalbuminuria included in the Irbesartan Diabetic Nephropathy Trial (IDNT) and Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trials, not in other individuals. The lack of new therapies to treat diabetic kidney disease over the past 2 decades has therefore represented a tremendous challenge for patients and health care providers alike. In recent years, a number of powerful new therapies have emerged that promise to transform care of patients with diabetes and kidney disease. The challenge to the community is to ensure rapid implementation of these treatments. This white paper highlights advances in treatment, opportunities for patients, challenges, and possible solutions to advance kidney health, and introduces the launch of the Diabetic Kidney Disease Collaborative at the American Society of Nephrology, to aid in accomplishing these goals.<\/jats:p>","DOI":"10.2215\/cjn.18641120","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T11:10:18Z","timestamp":1623150618000},"page":"1590-1600","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Transforming the Care of Patients with Diabetic Kidney Disease"],"prefix":"10.2215","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct01131676","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01730534","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01986881","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02065791","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03036150","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03594110","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03057977","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02540993","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01858532","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03819153","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Frank C.","family":"Brosius","sequence":"first","affiliation":[{"name":"Division of Nephrology, University of Arizona College of Medicine, Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cherney","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8442-481X","authenticated-orcid":false,"given":"Patrick O.","family":"Gee","sequence":"additional","affiliation":[{"name":"Kidney Health Initiative's Patient and Family Partnership Council, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond C.","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Kliger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Washington, & Providence Health Care, Spokane, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Quaggin","sequence":"additional","affiliation":[{"name":"Feinberg Cardiovascular and Renal Research Institute and the Division of Nephrology & Hypertension, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","article-title":"The global epidemiology of diabetes and kidney disease","volume":"25","author":"Koye","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: Results from the DAPA-HF Trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.2215\/CJN.00580111","article-title":"Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death","volume":"6","author":"Berhane","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1172\/JCI72271","article-title":"Molecular mechanisms of diabetic kidney disease","volume":"124","author":"Reidy","year":"2014","journal-title":"J Clin Invest"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3390\/jcm4111908","article-title":"Renin-angiotensin-aldosterone system blockade in diabetic nephropathy. Present evidences","volume":"4","author":"Lozano-Maneiro","year":"2015","journal-title":"J Clin Med"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.hjh.0000191244.91314.9d","article-title":"Blockade of the renin-angiotensin-aldosterone system: A key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes","volume":"24","author":"Burnier","year":"2006","journal-title":"J Hypertens"},{"key":"B8-20241015","first-page":"8","article-title":"ACE inhibitor slows onset of renal disease in diabetics by 50%","volume":"7","author":"Lefton","year":"1993","journal-title":"Nephrol News Issues"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"e1918169","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical characteristics of and risk factors for chronic kidney disease among adults and children: An analysis of the CURE-CKD Registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1681\/ASN.2018100971","article-title":"Trends in angiotensin-converting enzyme inhibitor and angiotensin ii receptor blocker use among those with impaired kidney function in the United States","volume":"30","author":"Murphy","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12933-019-0903-4","article-title":"Class effects of SGLT2 inhibitors on cardiorenal outcomes","volume":"18","author":"Kluger","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: An analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.kint.2020.12.006","article-title":"Importance of standardizing renal outcomes in clinical trials: Illustration by recent sodium glucose cotransporter 2 inhibitor studies","volume":"99","author":"van Raalte","year":"2021","journal-title":"Kidney Int"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cmet.2019.10.008","article-title":"The DAPA-HF Trial: A momentous victory in the war against heart failure","volume":"30","author":"Bhatt","year":"2019","journal-title":"Cell Metab"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B20-20241015","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"E624","DOI":"10.9778\/cmajo.20190065","article-title":"Identifying Ontario geographic regions to assess adults who present to hospital with laboratory-defined conditions: A descriptive study","volume":"7","author":"Iskander","year":"2019","journal-title":"CMAJ Open"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(20)30313-2","article-title":"Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: A post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials","volume":"8","author":"Mann","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B25-20241015","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B26-20241015","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B27-20241015","doi-asserted-by":"crossref","first-page":"254","DOI":"10.34067\/KID.0005852020","article-title":"Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: AWARD-7 exploratory analysis","volume":"2","author":"Tuttle","year":"2021","journal-title":"Kidney360"},{"key":"B28-20241015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B29-20241015","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B30-20241015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41440-018-0158-6","article-title":"Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease","volume":"42","author":"Nishiyama","year":"2019","journal-title":"Hypertens Res"},{"key":"B31-20241015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"B32-20241015","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"B33-20241015","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"B34-20241015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2215\/CJN.07820719","article-title":"Preserving kidney function instead of replacing it","volume":"15","author":"Kliger","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B35-20241015","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.kint.2020.10.003","article-title":"Therapeutic transformation for diabetic kidney disease","volume":"99","author":"Tuttle","year":"2021","journal-title":"Kidney Int"},{"key":"B36-20241015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/j.ajkd.2020.01.007","article-title":"CKD awareness among US adults by future risk of kidney failure","volume":"76","author":"Chu","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B37-20241015","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2337\/dbi18-0007","article-title":"Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease","volume":"68","author":"Alicic","year":"2019","journal-title":"Diabetes"},{"key":"B38-20241015","doi-asserted-by":"crossref","first-page":"2054358120935701","DOI":"10.1177\/2054358120935701","article-title":"Sodium-glucose cotransporter-2 inhibitors in nephrology practice: A narrative review","volume":"7","author":"Dubrofsky","year":"2020","journal-title":"Can J Kidney Health Dis"},{"key":"B39-20241015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2215\/CJN.18881220","article-title":"SGLT2 inhibitors in diabetic kidney disease","volume":"16","author":"Zoungas","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B40-20241015","doi-asserted-by":"crossref","first-page":"e2020969","DOI":"10.1001\/jamanetworkopen.2020.20969","article-title":"Coverage, formulary restrictions, and out-of-pocket costs for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in the Medicare Part D Program","volume":"3","author":"Luo","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B41-20241015","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jcjd.2017.08.244","article-title":"The effectiveness of pharmacist interventions on cardiovascular risk in adult patients with type 2 diabetes: The multicentre randomized controlled RxEACH Trial","volume":"41","author":"Al Hamarneh","year":"2017","journal-title":"Can J Diabetes"},{"key":"B42-20241015","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","article-title":"Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: A scientific statement from the American Heart Association","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation"},{"key":"B43-20241015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1077558711430690","article-title":"A compilation of strategies for implementing clinical innovations in health and mental health","volume":"69","author":"Powell","year":"2012","journal-title":"Med Care Res Rev"},{"key":"B44-20241015","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1001\/jama.2016.3867","article-title":"Convergence of implementation science, precision medicine, and the learning health care system: A new model for biomedical research","volume":"315","author":"Chambers","year":"2016","journal-title":"JAMA"},{"key":"B45-20241015","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B46-20241015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B47-20241015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B48-20241015","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.18641120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:48Z","timestamp":1786369488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.18641120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.18641120","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}